Dr. Olga Kubassova, CEO of IAG will be speaking at Precision Medicine in Autoimmunity
Growing influence of Precision Medicine will impact drug development and patient journey of tomorrow, probably beyond what we can imagine or predict today. We believe that within a few years, the treatment and diagnosis of the diseases will be guided through targeted therapies; and personalized care will be an essential component of our every day life and critical step for prevention of many conditions.
CEO of IAG, Dr. Olga Kubassova will be speaking at Digital Transformation and Precision Medicine Virtual Conference, 11-12 June 2020. Her talk, titled ‘Advanced Imaging and AI for Clinical Drug Development: Autoimmunity’ will cover the state of the art scoring and novel AI and Machine Learning driven imaging based biomarkers used in the assessment of treatment response in auto-immune diseases. Scientific program is available here!
SESSION: ARTIFICIAL INTELLIGENCE, BLOCKCHAIN & OTHER DISRUPTERS
12:40 EDT: ‘Advanced Imaging and AI for Clinical Drug Development: Autoimmunity’
• The connection between the development of novel therapeutics and data sciences
• The practical use of imaging in clinical trials: patient stratification and drug efficacy
• Modern trial infrastructure to enable global reach and use of AI
About Digital Transformation and Precision Medicine Virtual Conference
The conference will focus on the innovative and disruptive digital health technologies and futuristic business models transforming the precision medicine industry. The conference further aims in bringing experts from the academics, pharma, startups, hospitals and technology providers who will share their recent technological breakthroughs in personalized medicine.
About Olga Kubassova
Dr. Olga Kubassova is a mathematician by background with MS in Mathematics from St. Petersburg State University, Russia, MS in Information Technology from Lappeenranta University of Technology, Finland and a PhD in Computer Science from the University of Leeds, UK. Dr. Olga Kubassova is the founding scientist and CEO of IAG, Image Analysis Group, an imaging expert company. She started IAG straight after her PhD with an idea to bring the best of mathematics and computer science to optimize clinical development process while using imaging derived biomarkers to reliably and objectively assess efficacy of a novel drug.
About IAG, Image Analysis Group
Today IAG is a recognized partner to many blue-chip pharma companies in rheumatology, oncology and neurology. Since completing her PhD research in the area of MRI algorithm development for musculoskeletal disorders, Olga has been a significant contributor to the development of MRI as a clinical research and diagnostic tool in rheumatoid arthritis, osteoarthritis and other inflammatory joint diseases. She has co-authored over 60 articles, 7 book chapters and a number of abstracts that have built a significant evidence base for the medical imaging as a sensitive and objective biomarker for the assessment of various diseases and as an early measure of efficacy of new drugs. Olga is an active researcher, scientific adviser to the UK government and EU funding bodies, inc. European Commission, Innovative Medicines Initiative; she is an editor and reviewer of several scientific journals.